Citius Pharmaceuticals News

Express News | Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

ReutersApr 30 16:05 ET

Express News | Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

ReutersApr 26 08:00 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)

BenzingaApr 18 08:09 ET

Express News | University Of Minnesota Masonic Cancer Center Intends To Expand Cirtrus Pharmaceuticals' Ongoing Investigator-Initiated Phase 1 Trial Of LYMPHIR In Combination With FDA-Approved CAR-T Products For B-cell Lymphomas

Moomoo 24/7Apr 11 08:40 ET

Express News | Citius Pharmaceuticals Announces Addition of City of Hope to Umn's Phase 1 Trial of Lymphir in Combination With CAR-T for the Treatment of B-Cell Lymphoma

Moomoo 24/7Apr 11 08:30 ET

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireApr 4 08:30 ET

Positive Outlook for Citius Pharmaceuticals With Lymphir's FDA Resubmission and Market Potential

TipRanksMar 20 13:25 ET

Citius Pharma's LYMPHIR BLA Accepted by FDA, Decision by August 13

Citius Pharmaceuticals, Inc. (NASDAQ: NASDAQ:CTXR), a late-stage biopharmaceutical company, has announced the FDA's acceptance of its resubmitted Biologics License Application (BLA) for LYMPHIR™, an immunotherapy treatment for cutaneous T-cell lymphoma (CTCL).

Investing.com Mar 18 08:40 ET

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIRTM (Denileukin Diftitox) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireMar 18 08:30 ET

Nasdaq Grants Citius Pharmaceuticals Compliance Extension

InvestingMar 13 17:22 ET

Citius Pharmaceuticals, Inc. Secures $2.4 Million Through New Jersey Economic Development Program

PRNewswireMar 7 08:30 ET

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireFeb 26 07:30 ET

Citius Pharmaceuticals Files for $250M Mixed Securities Shelf

Seeking AlphaFeb 23 16:38 ET

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...

PR NewswireFeb 23 08:30 ET

Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)

TipRanksFeb 23 06:31 ET

Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)

TipRanksFeb 15 14:20 ET

Citius Pharmaceuticals GAAP EPS of -$0.06

Seeking AlphaFeb 14 16:38 ET

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Feb. 14, 2024 Resubmitted LYMPHIR(TM) Biologics License App

Dow JonesFeb 14 16:30 ET

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%. The iShares Biotechnology ETF (IBB) advanced 1.

MT NewswiresFeb 14 15:56 ET

Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment

Citius Pharmaceuticals (CTXR) said Wednesday it resubmitted its biologics license application for lymphoma treatment Lymphir with the US Food and Drug Administration . Citius said it has addressed con

MT NewswiresFeb 14 14:33 ET